GlobeNewsWire · 2 Oct 2026neutral
Syndax Pharmaceuticals announced that on October 1, 2026, it granted inducement awards to purchase up to 213,300 shares of common stock to nine new employees under its 2023 Inducement Plan. The stock options vest over four years, with 25% vesting on the one-year anniversary and the remainder monthly over the subsequent 36 months, subject to continued employment.
Why it matters — Inducement grants signal new employee hires and future share dilution for existing stockholders, which SNDX watchers may track in assessing the company's equity base.
Seeking Alpha · 28 Sept 2026positive
Syndax Pharmaceuticals was rated a "Strong Buy," driven by label expansion and revenue growth for Revuforj and Niktimvo. The company received FDA approval for Revuforj in relapsed/refractory mNPM1 AML, is pursuing pivotal studies in first-line AML, and is advancing Niktimvo into IPF and first-line cGVHD, with key phase 2 data readouts expected in Q4 2026.
Why it matters — SNDX watchers would care because the company's label-expansion pipeline for both Revuforj and Niktimvo points to significant upcoming catalysts, including pivotal studies and phase 2 data readouts scheduled for Q4 2026.
Seeking Alpha · 25 Sept 2026positive
Seeking Alpha highlights Syndax Pharmaceuticals' growth outlook driven by Revuforj and Niktimvo, with management reiterating over $2 billion in U.S. peak sales for Revuforj. Recent SAVE trial data showed an 88% overall response rate in AML with strong MRD negativity, while the pipeline includes next-generation menin and EGFR inhibitors targeting myelofibrosis and NSCLC.
Why it matters — SNDX watchers would care because the encouraging SAVE trial data could de-risk the ongoing Phase 3 trials and support expanded real-world use of Revuforj ahead of upcoming Q4 readouts.
Seeking Alpha · 10 Sept 2026neutral
Syndax Pharmaceuticals presented at Citigroup's Biopharma Back to School Summit 2026, and a transcript of the presentation was published by Seeking Alpha. The item reflects the company's participation in the investor conference.
Why it matters — SNDX watchers would care because the presentation transcript offers insight into what company executives discussed with investors at a major industry conference.
GlobeNewsWire · 4 Sept 2026neutral
Syndax Pharmaceuticals announced that on September 1, 2026, it granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under its 2023 Inducement Plan. The stock options vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly over the following 36 months, subject to continued employment.
Why it matters — This item is relevant to SNDX watchers as it details a routine equity inducement grant tied to hiring new employees, disclosed under Nasdaq Listing Rule 5635(c)(4).
